Role of Rosiglitazone on Pre-Diabetes Mellitus and Coronary Artery Disease
Status:
Completed
Trial end date:
2011-07-01
Target enrollment:
Participant gender:
Summary
Objectives:
The investigators examined whether rosiglitazone, a thiazolidinedione (TZD), is beneficial
for pre-diabetes mellitus (DM) adults with documented coronary artery disease (CAD).
Background:
Microvascular and macrovascular complications are common in type 2 DM. There is no evidence
about the effects of TZDs, synthetic peroxisome proliferator-activated receptor (PPAR)-γ
activators (insulin sensitizers and adipose transcriptional regulation and anti-inflammatory
process activators) on pre-DM patients with documented CAD.